Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Psilocybin/Immunology & Inflammation

Psilocybin for Immunology & Inflammation

23 papers and 8 clinical trials exploring psilocybin as a treatment for immunology & inflammation.

CompoundClassic Psychedelic

Psilocybin

Psilocybin is a naturally occurring tryptamine psychedelic that acts as a prodrug to psilocin, a potent 5-HT2A receptor agonist. It is the furthest advanced psychedelic in clinical development, with two positive Phase III trials in treatment-resistant depression and expanding regulated access in Australia, Germany, and US states.

Full Psilocybin profile
IndicationOver 264 million people worldwide suffer from depression, with a significant subset experiencing related inflammatory conditions.

Immunology & Inflammation

Recent research highlights the potential of psychedelics, particularly psilocybin and MDMA, in modulating immune responses and inflammation, shedding light on their therapeutic implications for mood disorders and other immune-related conditions. Studies are beginning to uncover the mechanisms through which these compounds exert anti-inflammatory effects and promote neuroplasticity, particularly in the context of major depressive disorder (MDD).

Full Immunology & Inflammation profile

Academic Research

23 papers
Open Accessindividual

Pilot study of psilocybin in patients with post-treatment lyme disease

In an open‑label, single‑arm pilot study of 20 patients with post‑treatment Lyme disease, two psilocybin sessions with psychological support produced significant, sustained reductions in symptom burden (40% decrease in GSQ‑30 at six months) and improvements in both physical and mental quality of life. The intervention was feasible and well-tolerated with no serious related adverse events, supporting further controlled trials of psilocybin‑assisted therapy for PTLD.

Published
February 25, 2026
Journal
Scientific Reports
Authors
Garcia-Romeu, A., Naudé, G. P., Rebman, A. W., So, S., Yaffe, A., Geithner, I., Kozero, E. A., Yang, T., Soloski, M. J., Aucott, J. N.
Open Accessindividual

Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial

In an open‑label pilot of 12 people with mild–moderate Parkinson’s disease and comorbid depression/anxiety, two psilocybin doses combined with psychotherapy were well tolerated with no serious adverse events. Participants showed clinically meaningful, sustained improvements in depression and anxiety and gains in non‑motor, motor and select cognitive measures up to three months post‑treatment, indicating psilocybin therapy in PD warrants further study.

Published
April 9, 2025
Journal
Neuropsychopharmacology
Authors
Bradley, E. R., Sakai, K., Fernandes-Osterhold, G., Szigeti, B., Ludwig, C., Ostrem, J. L., Tanner, C. M., Bock, M. A., Llerena, K., Finley, P. R., O'donovan, A., Rafael, J., Zuzuarregui, P., Busby, Z., Mckernan, A., Penn, A. D., Wang, A. C. C., Rosen, R. C., Woolley, J. D.
Paywallindividual

Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study

This double-blind placebo-controlled paper (n=60) explores the effects psilocybin (12mg/70kg) has on a range of inflammatory markers associated with stress-related psychiatric disorders. Blood samples, MRI and questionnaires were used to assess different aspects of the immune response. Psilocybin immediately reduced levels of the inflammation-inducing TNF-α while other markers were unchanged. After seven days, TNF-α returned to baseline while levels of IL-6 and CRP were reduced in the psilocybin group, which were associated with more persisting positive mood and social effects.

Published
November 1, 2023
Journal
Brain Behavior and Immunity - Health
Authors
Mason, N. L., Szabo, A., Kuypers, K. P. C., Mallaroni, P., de la Torre, R., Reckweg, J., Tse, D. H. Y., Hutten, N. P. W., Ramaekers, J. G.
Paywallindividual

Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD

This case report (n=3) documents the first academic instances of olfactory improvement after psychedelic use. The study also discusses potential mechanisms, such as serotonergic effects, neuroplasticity, and anti-inflammatory effects, suggesting further research into psychedelics for olfactory dysfunction.

Published
August 31, 2023
Journal
Journal of Psychoactive Drugs
Authors
Kovacevich, A., Weleff, J., Claytor, B., Barnett, B. S.
Open Accessindividual

The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study

This case study (n=1) describes an immunocompetent male with neuropsychiatric Lyme disease who did not respond to conventional treatments. However, his symptoms improved when he started using psilocybin in sub-hallucinogenic doses. Psilocybin is both serotonergic and anti-inflammatory, which may benefit patients with mental illness secondary to autoimmune inflammation.

Published
March 1, 2023
Journal
International Medical Case Reports Journal
Authors
Kinderlehrer, D. A.
Open Accessindividual

Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation

This open-label study (n=16) assessed the effects of a single dose of psilocybin (15mg/70kg) on biomarkers of inflammation in healthy participants. Blood samples before and one day after the administration revealed that psilocybin did not significantly impact any of the selected biomarkers.

Published
February 1, 2023
Journal
Comprehensive Psychoneuroendocrinology
Authors
Burmester, D., Madsen, M. K., Szabo, A., Aripaka, S. S., Stenbæk, D. S., Frokjaer, V. G., Elfving, B., Mikkelsen, J. D., Knudsen, G. M., Fisher, P. M.

Clinical Trials

8 trials
RecruitingPhase I

Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers

This Phase I, open-label, dose-escalation trial (n=10) will evaluate the safety and psychological effects of a combined psilocybin and D-Serine formulation; cohort 1 will receive psilocybin 15 mg with D-Serine 5 g, and if safe cohort 2 will receive psilocybin 25 mg with D-Serine 7 g.

Started
November 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT07079930
RecruitingPhase II

TRIPS – Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

This open-label, Phase II trial (n=20) will investigate the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors experiencing depression and/or anxiety.

Started
June 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06801041
RecruitingPhase II

Stress Experience Following Psilocybin (SEP-1)

This quadruple-blind, placebo-controlled trial (n=36) will investigate the role of stress response in shaping the positive effects of psilocybin (25mg or 1mg) by using metyrapone (750mg) to suppress cortisol production.

Started
February 1, 2025
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06768944
CompletedPhase II

Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers

Single-masked, randomised controlled trial (n=60) comparing psilocybin (two high-dose oral sessions, 5–6 g each, six weeks apart), CBT (8–10 sessions), psilocybin-assisted CBT, and routine care in adults with MDD.

Started
December 1, 2024
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
NCT06746441
Temporarily not availablePhase II

An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome

This open-label trial (n=10) will examine low-dose psilocybin as a safe treatment alternative for Fragile X Syndrome (FXS), aiming to improve markers of cognition, communication, mood, behaviour, neuroinflammation, serotonin levels in exosomes, and neuroplasticity.

Started
March 28, 2023
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT05832255
CompletedPhase I

PsilOCD: A Pharmacological-Challenge Feasibility Study

Single-group mechanistic feasibility study (n=19) administering up to 10 mg psilocybin (COMP360) on two occasions to people with OCD to assess cognitive inflexibility, neuroplasticity, and symptom changes.

Started
October 28, 2022
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06258031

Explore further

Search all Psilocybin papers Search all Immunology & Inflammation trials Full Psilocybin profile Full Immunology & Inflammation profile